Sugi Predict

Sugi Predict / Compounds / 2,6-Diaminopurine

2,6-Diaminopurine

2,6-Diaminopurine

SCHEMBL443468

Nc1nc(N)c2[nH]cnc2n1.OC[C@H]1OC[C@H](O)[C@@H]1O

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 1/20 0.55
▸ GDA Q9Y2T3 1/20 0.55
▸ CDK2 P24941 13/20 0.40
▸ DPP4 P27487 1/20 0.40
▸ CDK1 P06493 12/20 0.39
▸ CCNB1 P14635 12/20 0.39
▸ CCNA2 P20248 12/20 0.39
▸ CCNA1 P78396 12/20 0.39
▸ MAP3K5 Q99683 2/20 0.39
▸ PIN1 Q13526 2/20 0.39
▸ CCNB2 O95067 1/20 0.39
▸ MAPK3 P27361 1/20 0.39
▸ CLK1 P49759 1/20 0.39
▸ CDK5 Q00535 1/20 0.39
▸ CCNB3 Q8WWL7 1/20 0.39
▸ MGMT P16455 7/20 0.38
▸ ADORA2A P29274 1/20 0.36
▸ ADORA1 P30542 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15602792 0.88 PDPK1 (0.40) PDPK1GDACDK2DPP4CDK1
Adenine SCHEMBL593934 0.84 PI4KA (0.54) PDPK1GDACDK2CDK1
2,6-Diaminopurine SCHEMBL6241914 0.81 PDPK1 (0.59) PDPK1GDACDK2DPP4CDK1
2,6-Diaminopurine SCHEMBL10774603 0.81 PDPK1 (0.59) PDPK1GDACDK2DPP4CDK1
2,6-Diaminopurine SCHEMBL2934952 0.81 PDPK1 (0.59) PDPK1GDACDK2DPP4CDK1
2-Aminopurine SCHEMBL1507729 0.81 ALDH1A1 (0.55) PDPK1GDACDK2CDK1CCNB1
2,6-Diaminopurine SCHEMBL7801065 0.81 PDPK1 (0.55) PDPK1GDACDK2DPP4CDK1
Guanine SCHEMBL4198112 0.81 PNP (0.58) GDA
Hypoxanthine SCHEMBL4367641 0.76 LMNA (0.39) PDPK1CDK2CDK1
SCHEMBL2983115 0.75 PDPK1 (0.45) PDPK1GDACDK2DPP4CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3044228-B1 HIGHLY EFFICIENT SYNTHESIS OF LONG RNA USING REVERSE DIRECTION APPROACH CHEMGENES CORP (US) 2021-04-07 — — EP disclosed
CN-105916873-B Efficient synthesis of long RNAs using the reverse method 坎姆根公司 2020-06-19 — — CN disclosed
US-10167308-B2 Highly efficient synthesis of long RNA using reverse direction approach CHEMGENES CORPORATION (US) 2019-01-01 — — US disclosed
US-9969764-B2 Dithiolane functionalized nucleoside amidites and supports for stronger immobilization of bio-molecules on solid surfaces CHEMGENES CORPORATION 2018-05-15 — — US disclosed
US-9884885-B2 Synthesis of labile base protected-modified deoxy and modified ribo nucleosides, corresponding phosphoramidites and supports and their use in high purity oligonucleotide synthesis CHEMGENES CORPORATION (US) 2018-02-06 — — US disclosed
US-9605261-B2 RNA synthesis—phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end CHEMGENES CORPORATION (US) 2017-03-28 — — US disclosed
US-20170037076-A1 DITHIOLANE FUNCTIONALIZED NUCLEOSIDE AMIDITES AND SUPPORTS FOR STRONGER IMMOBILIZATION OF BIO-MOLECULES ON SOLID SURFACES CHEMGENES CORPORATION 2017-02-09 — — US disclosed
EP-2326656-B1 RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END CHEMGENES CORP (US) 2017-01-25 — — EP disclosed
US-9464106-B2 Oligonucleotides useful for detecting and analyzing nucleic acids of interest EXIQON A/S (DK) 2016-10-11 — — US disclosed
EP-3060572-A1 DITHIOLANE FUNCTIONALIZED NUCLEOSIDE AMIDITES AND SUPPORTS FOR STRONGER IMMOBILIZATION OF BIO-MOLECULES ON SOLID SURFACES Chemgenes Corporation (US) 2016-08-31 — — EP disclosed
EP-0639582-A2 Polynucleotide assay reagent and method ANTIVIRALS INC. (US) 1995-02-22 — — EP disclosed
US-5217866-A Polynucleotide assay reagent and method ANTI-GENE DEVELOPMENT GROUP (US) 1993-06-08 — — US disclosed
EP-0216860-B1 STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS SUMMERTON, James (US) 1992-10-28 — — EP disclosed
US-5142047-A Morpholino nucleosides for blocking targeted genetic sequence ANTI-GENE DEVELOPMENT GROUP (US) 1992-08-25 — — US disclosed
EP-0216860-A4 STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS. SUMMERTON JAMES (US) 1989-02-22 — — EP disclosed
EP-0215942-A4 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. SUMMERTON JAMES 1988-08-23 — — EP disclosed
EP-0216860-A1 STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS. SUMMERTON JAMES (US) 1987-04-08 — — EP disclosed
EP-0215942-A1 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. SUMMERTON JAMES 1987-04-01 — — EP disclosed
WO-1986005518-A1 STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS SUMMERTON JAMES 1986-09-25 — — WO disclosed
WO-1986005519-A1 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD SUMMERTON JAMES 1986-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10167308-B2 Highly efficient synthesis of long RNA using reverse direction approach NSUN3, POLRMT, METTL16 PDPK1 4364/4885GDA 2443/4885CDK2 3575/4885
US-20170037076-A1 DITHIOLANE FUNCTIONALIZED NUCLEOSIDE AMIDITES AND SUPPORTS FOR STRONGER IMMOBILIZATION OF BIO-MOLECULES ON SOLID SURFACES RNGTT, DIMT1, ADAR PDPK1 3429/4885GDA 485/4885CDK2 3121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.